Publications by authors named "D Rnjak"
Nintedanib treatment for bleomycin-induced lung injury - First report.
Respir Med Case Rep
September 2023
Article Synopsis
- Bleomycin, an antineoplastic agent used for over 50 years, poses significant pulmonary toxicity risks, potentially affecting 10% of patients.
- The exact mechanisms behind its pharmacological effects and side effects remain unclear, complicating treatment.
- A case report highlights a successful use of nintedanib for a patient with bleomycin-induced lung injury, emphasizing the need for more research and clinical trials in managing these toxicities.
During the ongoing COVID-19 epidemic many efforts have gone into the investigation of the SARS-CoV-2-specific antibodies as possible therapeutics. Currently, conclusions cannot be drawn due to the lack of standardization in antibody assessments. Here we describe an approach of establishing antibody characterisation in emergent times which would, if followed, enable comparison of results from different studies.
View Article and Find Full Text PDFAsthma is the most common respiratory disease. It has multiple phenotypes thatcan be partially differentiated by measuring the disease's specific characteristics-biomarkers. The pathogenetic mechanisms are complex, and it is still a challenge to choose suitable biomarkers to adequately stratify patients, which became especially important with the introduction of biologicals in asthma treatment.
View Article and Find Full Text PDF